ACURA PHARMACEUTICALS, INC Form 8-K January 31, 2008

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549

#### FORM 8-K

# CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934

**January 31, 2008** 

Date of Report (Date of earliest event reported)

### ACURA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

State of New York

(State of Other Jurisdiction of Incorporation)

1-10113 (Commission File Number)

11-0853640

(I.R.S. Employer Identification Number)

616 N. North Court, Suite 120 Palatine, Illinois 60067

(Address of principal executive offices) (Zip Code)

(847) 705-7709

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

#### Item 8.01 Other Events.

On February 4, 2008, our common stock will be listed on and begin trading on the NASDAQ Capital Market<sup>®</sup> under the symbol "ACUR". A press release announcing this development is being furnished as Exhibit 99.1 hereto.

#### Item 9.01 Financial Statements and Exhibits.

| Exhibit       |                    |
|---------------|--------------------|
| <u>Number</u> | <b>Description</b> |

99.1 Press Release dated January 31, 2008 Announcing Commencement of Trading on the NASDAQ Capital Market® on February 4, 2008

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

# ACURA PHARMACEUTICALS, INC.

By: /s/ Peter A. Clemens

Peter A. Clemens Senior Vice President & Chief Financial Officer

Date: January 31, 2008

# **EXHIBIT INDEX**

# Exhibit Number Description

99.1 Press Release dated January 31, 2008 Announcing Commencement of Trading on the NASDAQ Capital Market® on February 4, 2008